Hematopoietic and Lymphatic System NeoplasmNCT02474160

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

An observational study of Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, run by National Cancer Institute LAO at 140 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs. Read more about this study

Who is it for?: Ages 2 months and older
Conditions the study is for: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
What is being tested?: Cytology Specimen Collection Procedure
How many people: 5,000 participants
Where: 140 sitesUnited States
Study dates: 19 May 2015to 4 May 2028
Phase: Observational
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 2 months and older
All sexes
No healthy volunteers
Child, Adult, Older adult

Study population: Patients undergoing evaluation and/or treatment for cancer

Who may be able to join

Patients older than 2 months of age who are being evaluated, treated, or enrolled in a clinical trial for cancer at participating sites
Patients with a histologically or cytologically confirmed diagnosis of cancer
Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator
Requests for coordinating site approval should only be made if the patient's existing work-up at the time of the request demonstrates a combination of two or more of the following indicating the greater likelihood of a cancerous process in the assessment of the treating physician:
Radiographic imaging (computed tomography [CT], magnetic resonance imaging [MRI], etc.)
Elevated tumor markers

Show all 24Show fewer

Clinical symptoms
Documented risk factors, known genetic changes (mutation, deletion, fusion, etc.), and/or known familial cancer history or syndrome
Complete blood count (CBC) w/differential indicative of a probable hematologic malignancy
If the patient will be undergoing surgical resection at a later time and will be accessible to approach for study participation at that time, resected material following cancer diagnosis confirmation is preferred
Important: Additional medical, genetic and/or demographic work-up should not be obtained solely for determination of eligibility for protocol 9846 by these criteria. Once available, final histology must be confirmed to the coordinating site detailing the cancer diagnosis for patients enrolled based on the above criteria
Patients with a newly diagnosed primary and/or metastatic solid tumor or hematologic malignancy for which they have not yet received treatment
Patients with a solid tumor or hematologic malignancy that is recurrent, newly metastasized, or progressing while on treatment indicated by:
Radiographic evidence of tumor growth, re-growth, and/or new metastases, OR
Documentation by the treating physician of clinical disease progression, OR
CBC w/differential and/or flow cytometry for hematologic malignancies
Patients currently undergoing treatment (adjuvant, neoadjuvant, etc.)
Specimen collection should occur as distant in time from the most recent drug administration as possible (e.g., after completion of a treatment cycle and immediately prior to initiation of the next cycle)
Specimens should not be collected from patients between doses within a single treatment cycle
Confirmation of viable residual malignancy and/or < 90% tumor necrosis, fibrosis, or hemorrhage must be confirmed to the National Cancer Institute (NCI) coordinating site, as indicated in the final post-operative/post-procedure pathology and/or flow cytometry report
Patients with ongoing partial response (PR) or stable disease (SD) are eligible
Confirmation of viable malignancy and/or < 90% tumor necrosis, fibrosis, or hemorrhage must be confirmed to the NCI coordinating site, as indicated in the final post-operative/post-procedure pathology and/or flow cytometry report
Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol
For pediatric patients, ability and willingness to assent to participation, using an explanation that is understandable/age appropriate, as well as receiving parental permission. Signature requirements for pediatric patients can be adjusted based on local guidelines

Who cannot join

Patients with cancer-like syndromes and/or blood disorders such as systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)
Patients with invasive fungal infections
Patients with active and/or uncontrolled bacterial, fungal, or viral infections or who are still recovering from an infection
Actively febrile patients with uncertain etiology of febrile episode
All antibiotics prescribed for the treatment of a bacterial infection should be completed at least 1 week (7 days) prior to collection
Patients with a hematologic malignancy who are treated with an antibiotic, anti-fungal, and/or anti-viral medication for an active infection who then remain on the treatment for prophylaxis following resolution of the infection as assessed by the treating physician are not excluded

Show all 13Show fewer

No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
Patients receiving antibiotics, antifungals, and/or antivirals for prophylaxis are permissible
Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible
Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e., quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HCV, HBV, or HIV; testing for HBV, HCV, HIV or other infections for eligibility will be performed only if clinically indicated
Patients with hepatitis A as indicated by anti-hepatitis A virus (HAV) IgM reactivity
Patients that are anti-HAV IgG reactive only are eligible
Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR)

Trial locations and contacts

140 sites in 1 country. Contact the study team or a site near you to ask about taking part.

City, postcode or hospital

Sites recruiting now only

140 sites in 1 country

United States140 sites, 18 recruiting

Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, 48106
Active, not recruiting
PCR Oncology
Arroyo Grande, California, 93420
Active, not recruiting
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Active, not recruiting
Augusta University Medical Center
Augusta, Georgia, 30912
Site Public Contact, 706-721-2388, ga_cares@augusta.edu
Anand P. Jillella
Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045
Active, not recruiting
Virginia Mason Bainbridge Island Medical Center
Bainbridge Island, Washington, 98110
Active, not recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Active, not recruiting
Bronson Battle Creek
Battle Creek, Michigan, 49017
Suspended
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Suspended
OSF Saint Joseph Medical Center
Bloomington, Illinois, 61701
Active, not recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Suspended
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613
Suspended
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
Suspended
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Active, not recruiting
Cox Cancer Center Branson
Branson, Missouri, 65616
Suspended
Illinois CancerCare-Canton
Canton, Illinois, 61520
Suspended
Mercy Cancer Center - Cape Girardeau
Cape Girardeau, Missouri, 63703
Suspended
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Suspended
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Suspended
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Suspended
Centralia Oncology Clinic
Centralia, Illinois, 62801
Suspended
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Active, not recruiting
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Suspended
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
Site Public Contact, 312-864-5204
Deimante M. Tamkus
Recruiting
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
Active, not recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Active, not recruiting
Decatur Memorial Hospital
Decatur, Illinois, 62526
Active, not recruiting
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Active, not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Active, not recruiting
Duke University Medical Center
Durham, North Carolina, 27710
Active, not recruiting
Marshfield Clinic Cancer Center at Sacred Heart
Eau Claire, Wisconsin, 54701
Active, not recruiting
Crossroads Cancer Center
Effingham, Illinois, 62401
Suspended
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Active, not recruiting
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Suspended
Virginia Mason Federal Way Medical Center
Federal Way, Washington, 98002
Active, not recruiting
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Active, not recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas, 72903
Site Public Contact, 800-378-9373
Jay W. Carlson
Recruiting
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Suspended
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Suspended
MultiCare Gig Harbor Medical Park
Gig Harbor, Washington, 98335
Active, not recruiting
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan, 49503
Site Public Contact, 616-391-1230, crcwm-regulatory@crcwm.org
Kathleen Y. Butler
Recruiting
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan, 49503
Suspended
Cancer and Blood Specialists-Henderson
Henderson, Nevada, 89052
Active, not recruiting
UT MD Anderson Cancer Center
Houston, Texas, 77030
Active, not recruiting
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Active, not recruiting
MU Health Care Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Suspended
Freeman Health System
Joplin, Missouri, 64804
Site Public Contact, 417-347-4030, LJCrockett@freemanhealth.com
Jay W. Carlson
Recruiting
Mercy Hospital Joplin
Joplin, Missouri, 64804
Site Public Contact, 417-556-3074, esmeralda.carrillo@mercy.net
Jay W. Carlson
Recruiting
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Suspended
Beacon Kalamazoo
Kalamazoo, Michigan, 49048
Suspended
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Suspended
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Active, not recruiting
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Suspended
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, 89106
Active, not recruiting
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, 89109
Active, not recruiting
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, 89113
Active, not recruiting
Cancer Therapy and Integrative Medicine
Las Vegas, Nevada, 89121
Active, not recruiting
Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada, 89128
Active, not recruiting
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, 89128
Active, not recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
Active, not recruiting
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada, 89149
Active, not recruiting
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Active, not recruiting
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89183
Active, not recruiting
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Active, not recruiting
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Active, not recruiting
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Active, not recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Active, not recruiting
Virginia Mason Lynnwood Medical Center
Lynnwood, Washington, 98036
Active, not recruiting
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Suspended
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Active, not recruiting
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Active, not recruiting
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Site Public Contact, 901-226-1366, BCCclintrials@bmhcc.org
Raymond U. Osarogiagbon
Recruiting
Marshfield Medical Center - Minocqua
Minocqua, Wisconsin, 54548
Active, not recruiting
SSM Health Good Samaritan
Mount Vernon, Illinois, 62864
Site Public Contact, 618-899-1894, gayla.hall@ssmhealth.com
Jay W. Carlson
Recruiting
Trinity Health Muskegon Hospital
Muskegon, Michigan, 49444
Suspended
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510
Active, not recruiting
Yale University
New Haven, Connecticut, 06520
Active, not recruiting
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Site Public Contact, 212-342-5162, cancerclinicaltrials@cumc.columbia.edu
Bret Taback
Recruiting
Delaware Clinical and Laboratory Physicians PA
Newark, Delaware, 19713
Active, not recruiting
Helen F Graham Cancer Center
Newark, Delaware, 19713
Active, not recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Active, not recruiting
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Active, not recruiting
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Active, not recruiting
Corewell Health Lakeland Hospitals - Niles Hospital
Niles, Michigan, 49120
Suspended
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
Suspended
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
Site Public Contact, 405-752-3402
Jay W. Carlson
Recruiting
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Suspended
Radiation Oncology of Northern Illinois
Ottawa, Illinois, 61350
Suspended
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi, 38655
Site Public Contact, 901-226-1366, BCCclintrials@bmhcc.org
Raymond U. Osarogiagbon
Recruiting
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Active, not recruiting
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Suspended
OSF Saint Francis Radiation Oncology at Pekin
Pekin, Illinois, 61554
Suspended
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Suspended
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
Suspended
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Suspended
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Suspended
Illinois CancerCare-Peru
Peru, Illinois, 61354
Suspended
Valley Radiation Oncology
Peru, Illinois, 61354
Suspended
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Active, not recruiting
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Suspended
MultiCare Good Samaritan Hospital
Puyallup, Washington, 98372
Active, not recruiting
Corewell Health Reed City Hospital
Reed City, Michigan, 49677
Suspended
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin, 54868
Active, not recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Active, not recruiting
Mercy Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Suspended
Phelps Health Delbert Day Cancer Institute
Rolla, Missouri, 65401
Site Public Contact, 573-458-7504, research@phelpshealth.org
Jay W. Carlson
Recruiting
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Suspended
Corewell Health Lakeland Hospitals - Saint Joseph Hospital
Saint Joseph, Michigan, 49085
Suspended
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Site Public Contact, 816-271-7937, Trisha.England2@mymlc.com
Jay W. Carlson
Recruiting
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Suspended
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
Active, not recruiting
Virginia Mason Medical Center
Seattle, Washington, 98101
Active, not recruiting
Central Illinois Hematology Oncology Center
Springfield, Illinois, 62702
Active, not recruiting
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Suspended
Springfield Clinic
Springfield, Illinois, 62702
Suspended
Springfield Memorial Hospital
Springfield, Illinois, 62781
Suspended
Mercy Hospital Springfield
Springfield, Missouri, 65804
Site Public Contact, 417-269-4520
Jay W. Carlson
Recruiting
CoxHealth South Hospital
Springfield, Missouri, 65807
Site Public Contact, 417-269-4520
Jay W. Carlson
Recruiting
Mercy Infusion Center - Chippewa
St Louis, Missouri, 63109
Suspended
Washington University School of Medicine
St Louis, Missouri, 63110
Active, not recruiting
Mercy Hospital South
St Louis, Missouri, 63128
Site Public Contact, 314-525-6042, Danielle.Werle@mercy.net
Jay W. Carlson
Recruiting
Missouri Baptist Medical Center
St Louis, Missouri, 63131
Active, not recruiting
Mercy Hospital Saint Louis
St Louis, Missouri, 63141
Site Public Contact, 314-251-7066
Jay W. Carlson
Recruiting
Aspirus Cancer Care - Stevens Point
Stevens Point, Wisconsin, 54481
Active, not recruiting
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
Suspended
MultiCare Tacoma General Hospital
Tacoma, Washington, 98405
Site Public Contact, 253-403-3229, research@multicare.org
John A. Keech
Recruiting
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461
Active, not recruiting
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461
Active, not recruiting
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467
Active, not recruiting
Munson Medical Center
Traverse City, Michigan, 49684
Suspended
Marshfield Clinic-Wausau Center
Wausau, Wisconsin, 54401
Active, not recruiting
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Active, not recruiting
Marshfield Medical Center - Weston
Weston, Wisconsin, 54476
Active, not recruiting
Associates In Womens Health
Wichita, Kansas, 67208
Active, not recruiting
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas, 67208
Active, not recruiting
Ascension Via Christi Hospitals Wichita
Wichita, Kansas, 67214
Active, not recruiting
Cancer Center of Kansas - Wichita
Wichita, Kansas, 67214
Active, not recruiting
Wesley Medical Center
Wichita, Kansas, 67214
Active, not recruiting
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware, 19801
Active, not recruiting
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Active, not recruiting

Other trials in United States

About this study

Official title: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Read the detailed description

PRIMARY OBJECTIVE:

To procure biologic tissues and materials to generate preclinical models of cancer.

OUTLINE: This is an observational study.

Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and will be stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Being tested: Cytology Specimen Collection Procedure
Medical subject headings: Neoplasm Metastasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Cytology Specimen Collection ProcedureOther
Also called Cytologic Sampling
Procurement of tissue and blood samples

Study groups in NCT02474160
Study group	Role	What they receive
Observational (tissue and blood procurement)		Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis. Receives: Other: Cytology Specimen Collection Procedure

What is being measured

The primary outcome is the main question the study is designed to answer.

Procurement of tissue and blood specimens for research purposes
Tissues and venous blood will be stored, implanted immediately to generate patient-derived xenografts (which require fresh, viable cells), or placed immediately into in vitro cell culture to generate patient-derived cell lines (which require fresh, viable cells).
Measured: Up to 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

19 May 20154 May 2028

First posted17 Jun 2015 (estimated)
Study start19 May 2015
Primary completion4 May 2028 (estimated)
Study completion4 May 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Hematopoietic and Lymphatic System NeoplasmStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Case only
Time perspective: Prospective
Enrolment: 5,000 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT02474160
Sponsor's protocol ID: NCI-2015-00863
Other IDs: NCI-2015-00863, P9846, P9846_R02PAPPHOLD01, 9846, 9846, UM1CA186689, UM1CA186691, UM1CA186704
Status last verified: Oct 2026
First submitted: 15 Jun 2015
Last updated: 22 Oct 2026
Results posted: No
Data monitoring committee: No

Interested in taking part?

Each site lists its own contact. Pick the site nearest to you.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

RecruitingPhase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Malignancy, Hematologic, Neoplasms, Hematologic
Not yet recruitingPhase 2
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Core Binding Factor Alpha Subunits, Hematologic Neoplasms
RecruitingPhase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Recruiting
Different Types of Massage Therapy to Reduce Anxiety During Chemotherapy Infusion in Patients With Cancer
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Enrolling by invitationPhase 1/2
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
WHIM, Warts

All Hematopoietic and Lymphatic System Neoplasm trials

Study at a glance

From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
ClinicalTrials.gov ID: NCT02474160
Acronym / sponsor ID: NCI-2015-00863
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Study type: Observational
Recruitment status: Recruiting
Enrolment: 5,000 participants (estimated)
Lead sponsor: National Cancer Institute LAO
Collaborators: National Cancer Institute (NCI)
Study start: 19 May 2015 (actual)
Primary completion: 4 May 2028 (estimated)
Study completion: 4 May 2028 (estimated)
First posted: 17 Jun 2015 (estimated)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

PRIMARY OBJECTIVE:

To procure biologic tissues and materials to generate preclinical models of cancer.

OUTLINE: This is an observational study.

Study design

Observational model: Case only
Time perspective: Prospective
Number of arms: 1

Arm	Type	Receives
Observational (tissue and blood procurement)	–	Other: Cytology Specimen Collection ProcedureTumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.

Who may qualify

Ages: 2 months and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Child, Adult, Older adult
Study population: Patients undergoing evaluation and/or treatment for cancer

Key inclusion criteria (24 listed)

Patients older than 2 months of age who are being evaluated, treated, or enrolled in a clinical trial for cancer at participating sites
Patients with a histologically or cytologically confirmed diagnosis of cancer
Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator
Patients with a newly diagnosed primary and/or metastatic solid tumor or hematologic malignancy for which they have not yet received treatment
Patients with a solid tumor or hematologic malignancy that is recurrent, newly metastasized, or progressing while on treatment indicated by:

Key exclusion criteria (13 listed)

Patients with cancer-like syndromes and/or blood disorders such as systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)
Patients with invasive fungal infections
Patients with active and/or uncontrolled bacterial, fungal, or viral infections or who are still recovering from an infection
Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e., quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HCV, HBV, or HIV; testing for HBV, HCV, HIV or other infections for eligibility will be performed only if clinically indicated
Patients with hepatitis A as indicated by anti-hepatitis A virus (HAV) IgM reactivity

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Cytology Specimen Collection ProcedureAlso: Cytologic SamplingProcurement of tissue and blood samples	Other	Observational (tissue and blood procurement)

Primary outcome

Procurement of tissue and blood specimens for research purposes
Time frame: Up to 5 years
Tissues and venous blood will be stored, implanted immediately to generate patient-derived xenografts (which require fresh, viable cells), or placed immediately into in vitro cell culture to generate patient-derived cell lines (which require fresh, viable cells).

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.

Related trials for Hematopoietic and Lymphatic System Neoplasm

RecruitingPhase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Malignancy, Hematologic, Neoplasms, Hematologic
Not yet recruitingPhase 2
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Core Binding Factor Alpha Subunits, Hematologic Neoplasms
RecruitingPhase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Recruiting
Different Types of Massage Therapy to Reduce Anxiety During Chemotherapy Infusion in Patients With Cancer
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Enrolling by invitationPhase 1/2
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
WHIM, Warts

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Mercy Hospital Fort Smith

Fort Smith, United States

800-378-9373

Augusta University Medical Center

Augusta, United States

706-721-2388

ga_cares@augusta.edu

John H Stroger Jr Hospital of Cook County

Chicago, United States

312-864-5204

James H Doroshow principal investigator

National Cancer Institute (NCI)

140 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, run by National Cancer Institute LAO at 140 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 140 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Procurement of tissue and blood specimens for research purposes (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02474160.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.